Dermatomyositis Market
Number of pages: 100 | Report Format: PDF | Published date: April 12, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 515 million |
|
Market Size Value in 2031 |
US$ 745 million |
|
CAGR |
4.2% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Treatment Type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global dermatomyositis market was valued at US$ 515 million in 2022 and is expected to register a revenue CAGR of 4.2% to reach US$ 745 million by 2031.
Dermatomyositis Market Fundamentals
Dermatomyositis is a rare autoimmune disorder that primarily affects the muscles and skin. It is characterized by muscle weakness, skin rash, and inflammation and can affect people of all ages, although it is most common in adults between the ages of 40 and 60. Other organs, such as the lungs, heart, and gastrointestinal tract, may also be affected. The dermatomyositis cause is not fully understood, but it is believed to be related to an abnormal immune response in the body. There is currently no cure for dermatomyositis, but treatment options such as immunosuppressant drugs, immunoglobulin, and physical therapy can help manage symptoms and improve the quality of life for those affected.
The dermatomyositis market revenue growth is expected to be driven exponentially during the forecast period. The key dermatomyositis market trends include advancements in diagnostic technologies enabling appropriate patient population reporting and developing novel treatment options. Biopharmaceutical companies are investing in the research and development of new drugs for dermatomyositis, which is expected to expedite the market movement. Key companies operating in the market, such as Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., NovartisAG, Octapharma AG, and others, are intensely investing in research and development of novel therapies for dermatomyositis.
[87987]
Dermatomyositis Market Dynamics
The prevalence of autoimmune diseases, including dermatomyositis, is increasing globally. This is one of the primary drivers of the dermatomyositis market, as more people are diagnosed and seek treatment. As reported by Medscape, the expected cases of dermatomyositis are 9.63 cases per million population. Improved diagnostic technologies, including biomarker testing and imaging techniques, make diagnosing dermatomyositis easier. This may lead to earlier detection and treatment, improving patient outcomes. Biopharmaceutical companies are investing in researching and developing new drugs for dermatomyositis, including biologics and targeted therapies. These new treatment options are expected to provide patients with more effective and targeted treatment options propelling the revenue growth of dermatomyositis. Combination therapies, which involve using multiple drugs to treat dermatomyositis, are becoming more common. This approach may provide more effective treatment outcomes for patients with difficult-to-treat cases of dermatomyositis.
Moreover, awareness of dermatomyositis is increasing among patients and healthcare providers, leading to earlier detection and diagnosis of the disease, thus fueling the revenue growth of the dermatomyositis market. There is a growing trend toward patient-centered care in the dermatomyositis market, focusing on improving patients' quality of life. This may involve developing treatments that address not only the physical symptoms of the disease but also the psychological and social impacts. However, there are currently limited treatment options for dermatomyositis, restricting the growth of the dermatomyositis market. Most of the treatments may have significant side effects, cramping the growth of dermatomyositis market revenue.
Dermatomyositis Market Ecosystem
The global dermatomyositis market is analyzed from four perspectives: type, treatment type, distribution channel, and region.
Dermatomyositis Market by Type
[45645]
Based on the type, the global dermatomyositis market is segmented into adult dermatomyositis, dermatomyositis sine myositis, and juvenile dermatomyositis (JDM).
The adult dermatomyositis segment accounted for a significant market revenue share in 2022. Adult dermatomyositis is an autoimmune disorder that primarily affects the skin and muscles, causing muscle weakness and skin rash. It usually occurs in adults between the ages of 40 and 60, and it is more common in women than men. In addition, adult dermatomyositis is a chronic condition that requires ongoing treatment and management. Patients with adult dermatomyositis often require long-term use of medications, such as corticosteroids and immunosuppressants, to control their symptoms and prevent disease progression. This leads to a higher demand for medications and other treatments in the adult dermatomyositis market segment.
The juvenile dermatomyositis (JDM) segment is expected to witness a lucrative growth rate during the forecast period because juvenile dermatomyositis is a rare autoimmune disorder that primarily affects children under the age of 18. The incidence of juvenile dermatomyositis is increasing globally. According to Medscape, in the U.S., the annual incidence of juvenile dermatomyositis ranges from 2.5 to 4.1 cases per million population. This increase in incidence may be due to a combination of factors, including improved disease recognition, more accurate dermatomyositis diagnosis, and better access to healthcare. In addition, there is a growing interest in developing novel treatments for juvenile dermatomyositis, as current therapies have limitations and can cause significant side effects. This has led to increased research and development activities, driving the revenue growth of the juvenile dermatomyositis market.
Dermatomyositis Market by Treatment Type
Based on the treatment type, the global dermatomyositis market is segmented into anti-inflammatory medications, immunosuppressive drugs, immunoglobulin, and others.
The immunosuppressive drugs segment accounts for the largest dermatomyositis market revenue share. Being an autoimmune disorder, immunosuppressive drugs are the mainstay of treating this condition. Various types of immunosuppressive drugs are used to treat dermatomyositis, including methotrexate, azathioprine, mycophenolate mofetil, and rituximab. These drugs are typically used in combination with other medications, such as antimalarials and biologics, to achieve optimal disease control. In addition, dermatomyositis is a chronic condition that often requires long-term treatment with immunosuppressive drugs. Patients with dermatomyositis may require ongoing therapy with these drugs to prevent disease relapse and manage symptoms. This leads to a high demand for immunosuppressive drugs in the dermatomyositis market.
The anti-inflammatory medication segment accounted for a prominent revenue share of the dermatomyositis market. Anti-inflammatory medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), reduce inflammation, relieve pain, and improve muscle function. Corticosteroids are a potent anti-inflammatory medication that is commonly used to treat dermatomyositis. Corticosteroids are often used in combination with immunosuppressive drugs or antimalarials to achieve optimal disease control. In addition to reducing inflammation, anti-inflammatory medications also help to alleviate other symptoms, such as dermatomyositis rash, joint pain, and muscle weakness. They are typically used as part of a multidisciplinary approach to the management of dermatomyositis, which may also include physical therapy, occupational therapy, and other supportive measures. Therefore, the anti-inflammatory segment revenue growth is expected to remain steady during the forecast period due to the incumbent use in dermatomyositis treatment.
Dermatomyositis Market by Distribution Channel
Based on the distribution channel, the global dermatomyositis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for a significant revenue share of the dermatomyositis market in 2022. Dermatomyositis is a complex autoimmune disorder requiring specialized care and treatment. Hospital pharmacies are better equipped to handle the complex treatment regimens required for patients with dermatomyositis, as they provide access to a wider range of medications and specialized healthcare professionals. In many cases, patients with dermatomyositis require hospitalization for initial diagnosis and treatment, particularly if they are experiencing severe symptoms such as respiratory or cardiac involvement. Hospital pharmacies play a critical role in providing medications and monitoring patients' responses to therapy during hospitalization. The management of dermatomyositis requires a multidisciplinary approach involving various healthcare professionals, such as rheumatologists, dermatologists, neurologists, and physiotherapists. Hospital pharmacies have a greater capacity to collaborate and coordinate with these healthcare professionals under one roof to ensure that patients receive optimal care and treatment. Hospital pharmacies are better equipped to manage dermatomyositis treatment's potential side effects and complications, which can be significant, particularly with the long-term use of immunosuppressive drugs.
The online pharmacies segment is expected to witness a lucrative revenue CAGR during the forecast period. Online pharmacies offer a convenient way for patients to order their medications without leaving their homes, which is particularly important for patients who may have difficulty traveling to a physical pharmacy due to mobility or other health-related issues. Online pharmacies also offer a wider range of medications, including specialty medications that may not be available in retail pharmacies. The increased adoption of digital technology and the convenience of online ordering and delivery is a key trend observed in the healthcare industry. Online pharmacies offer various digital services, such as mobile apps and online portals, making it easy for patients to order their medications and track their deliveries. Online pharmacies may offer lower prices than traditional brick-and-mortar pharmacies, which can be particularly important for patients paying for their medications out of pocket. This price advantage has made online pharmacies an attractive option for patients with dermatomyositis and has contributed to segment revenue growth.
Dermatomyositis Market by Region
Geographically, the global dermatomyositis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America has the largest dermatomyositis market revenue share. Dermatomyositis is a rare but increasingly prevalent autoimmune disorder in North America, particularly among older adults. This has led to a growing demand for effective treatments and therapies for the condition. According to the National Organization for Rare Disorders, in the U.S., an estimated incidence of dermatomyositis is 9.63 cases per million people. North America has experienced significant advancements in treating dermatomyositis in recent years, particularly in the development of immunosuppressive drugs and biologics. These new treatments effectively manage dermatomyositis symptoms and contribute to the revenue growth of the North American dermatomyositis market. North America has a high level of healthcare expenditure, which has led to increased funding for research and development of new treatments for dermatomyositis. Improved diagnostic techniques and increased awareness among healthcare professionals have led to earlier and more accurate diagnoses of dermatomyositis, leading to improved treatment outcomes.
Competitive Landscape of the Global Dermatomyositis Market
The prominent players operating in the global dermatomyositis market are:
Strategic Developments in Dermatomyositis Market
Dermatomyositis is a rare autoimmune disorder that primarily affects the muscles and skin. It is characterized by muscle weakness, skin rash, and inflammation and can affect people of all ages, although it is most common in adults between the ages of 40 and 60.
The dermatomyositis market was valued at US$ 515 million in 2021.
The increasing prevalence of autoimmune diseases, advancements in diagnostic technologies, and the development of novel treatment options are some factors driving the global dermatomyositis market revenue growth.
The prominent players operating in the global dermatomyositis market are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Octapharma AG, and Corbus Pharmaceuticals Holdings Inc.
The adult dermatomyositis segment dominated the global dermatomyositis market.
*Insights on financial performance are subject to the availability of information in the public domain